Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI.
The impact of various types of intensification therapy was examined in a cohort of 3617 children aged 1-14 years with acute lymphoblastic leukaemia (ALL) enrolled in the Medical Research Council (MRC) UKALL X (1985-90) and UKALL XI (1990-97) trials. UKALL XI was modified in 1992 to incorporate the &...
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Journal article |
| اللغة: | English |
| منشور في: |
2002
|
| _version_ | 1826304937738371072 |
|---|---|
| author | Chessells, J Harrison, G Richards, S Gibson, B Bailey, C Hill, F Hann, I |
| author_facet | Chessells, J Harrison, G Richards, S Gibson, B Bailey, C Hill, F Hann, I |
| author_sort | Chessells, J |
| collection | OXFORD |
| description | The impact of various types of intensification therapy was examined in a cohort of 3617 children aged 1-14 years with acute lymphoblastic leukaemia (ALL) enrolled in the Medical Research Council (MRC) UKALL X (1985-90) and UKALL XI (1990-97) trials. UKALL XI was modified in 1992 to incorporate the "best arm" of UKALL X with two 5-d intensification blocks at 5 and 20 weeks, and an additional randomization in respect of a third intensification at 35 weeks but omission of two consecutive injections of daunorubicin during induction. All children were eligible for randomization irrespective of risk group. The impact of the various types of intensification therapy was examined in a stratified analysis. At a median follow up of 102 months, both trials had an identical event-free survival of 61% (95% CI 58-63%) at 8 years. Survival at 8 years in UKALL XI was significantly better in than in UKALL X, 81% (79-83%) compared with 74% (72-76%) (P = < 0.001), owing to improved management of relapse. There was a highly significant trend in reduction of the number of relapses and deaths with increased intensity of therapy both for children with initial leucocyte count < 50 x 10(9)/l (P = < 0.001) and > or = 50 x 10(9)/l (P = 0.002). Introduction of a third late intensification block compensated for omission of anthracyclines during induction but produced little additional benefit. These results show, in a large cohort of patients, that minor modifications of therapy may influence relapse rate and obviate the benefit of previous randomized trials. The failure to adapt treatment for higher risk children contributed to these disappointing results. |
| first_indexed | 2024-03-07T06:25:18Z |
| format | Journal article |
| id | oxford-uuid:f413aa9d-b917-4ccb-96db-ea1e6a80eb93 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:25:18Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:f413aa9d-b917-4ccb-96db-ea1e6a80eb932022-03-27T12:17:03ZFailure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f413aa9d-b917-4ccb-96db-ea1e6a80eb93EnglishSymplectic Elements at Oxford2002Chessells, JHarrison, GRichards, SGibson, BBailey, CHill, FHann, IThe impact of various types of intensification therapy was examined in a cohort of 3617 children aged 1-14 years with acute lymphoblastic leukaemia (ALL) enrolled in the Medical Research Council (MRC) UKALL X (1985-90) and UKALL XI (1990-97) trials. UKALL XI was modified in 1992 to incorporate the "best arm" of UKALL X with two 5-d intensification blocks at 5 and 20 weeks, and an additional randomization in respect of a third intensification at 35 weeks but omission of two consecutive injections of daunorubicin during induction. All children were eligible for randomization irrespective of risk group. The impact of the various types of intensification therapy was examined in a stratified analysis. At a median follow up of 102 months, both trials had an identical event-free survival of 61% (95% CI 58-63%) at 8 years. Survival at 8 years in UKALL XI was significantly better in than in UKALL X, 81% (79-83%) compared with 74% (72-76%) (P = < 0.001), owing to improved management of relapse. There was a highly significant trend in reduction of the number of relapses and deaths with increased intensity of therapy both for children with initial leucocyte count < 50 x 10(9)/l (P = < 0.001) and > or = 50 x 10(9)/l (P = 0.002). Introduction of a third late intensification block compensated for omission of anthracyclines during induction but produced little additional benefit. These results show, in a large cohort of patients, that minor modifications of therapy may influence relapse rate and obviate the benefit of previous randomized trials. The failure to adapt treatment for higher risk children contributed to these disappointing results. |
| spellingShingle | Chessells, J Harrison, G Richards, S Gibson, B Bailey, C Hill, F Hann, I Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title | Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title_full | Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title_fullStr | Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title_full_unstemmed | Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title_short | Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. |
| title_sort | failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia lessons from the uk medical research council trials ukall x and ukall xi |
| work_keys_str_mv | AT chessellsj failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT harrisong failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT richardss failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT gibsonb failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT baileyc failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT hillf failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi AT hanni failureofanewprotocoltoimprovetreatmentresultsinpaediatriclymphoblasticleukaemialessonsfromtheukmedicalresearchcounciltrialsukallxandukallxi |